NCT07774780Not yet recruiting
Oral Galactose as a Substrate for Post-Exercise Skeletal Muscle Glycogen Repletion in Individuals With Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
This Ph.D. project investigates whether orally ingested galactose can be taken up by skeletal muscle and the heart in response to exercise or hyperinsulinemia, and whether it may serve as a viable nutritional strategy for individuals with type 1 diabetes (T1D). Although exercise provides significant health benefits for people with T1D, it is often associated with substantial glucose fluctuations and an increased risk of hypoglycemia. Conventional carbohydrate strategies based on glucose may further exacerbate glycemic instability due to the rapid increase in blood glucose levels. In contrast, galactose is metabolized more slowly and may therefore provide a more stable energy source during and after exercise. Previous research has demonstrated that intravenously administered galactose is taken up by human skeletal muscle, with uptake increasing during exercise, suggesting a mechanism that may be at least partly insulin-independent. Building on these findings, this project aims to determine whether similar uptake occurs when galactose is ingested orally. This study uses a randomized controlled design and applies non-invasive 18F-FDGal PET imaging to quantify galactose uptake in skeletal muscle and cardiac tissue. The findings may contribute to improving dietary recommendations for individuals with T1D, particularly in relation to maintaining stable blood glucose levels during and after physical activity.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 10 Aug 2026
- Start date
- Feb 2027
- Primary completion date
- Sept 2028
- Lead sponsor
- University of Aarhus
- Diseases
- Type 1 diabetes
- NCT number
- NCT07774780
What you commit to
- Study type: Interventional
- Planned participants: 16
- From Feb 2027 to the primary completion date, Sept 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in other studies involving ionizing radiation within the last 6 months
Other illness
- Clinically significant heart, lung, kidney, liver, endocrine, or malignant disease based on information collected during the initial screening visit as well as blood tests
Other
- Lack of awareness of hypoglycemia episodes
- Blood donation within the last 3 months
- Smoking
- Alcohol or substance abuse
- Claustrophobia
- Inability to train one leg for one hour
Who the study is looking for
- Healthy or T1D
- BMI 18,5-30 kg/m2
- Singed informed consent
Age in the registry: 20 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aarhus Universitet Coordinator of this site? Confirm its status | Aarhus | Denmark | Unknown status |
| steno diabetes center Aarhus Coordinator of this site? Confirm its status | Aarhus | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.